Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s Strongest Pharmas Likely To Thrive Through Innovation And Acquisition Despite Global Crisis

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts predict the country’s top 100 pharmas will collectively post a rise in operating profit of more than 20 percent in 2009.

You may also be interested in...

China To Invest $1 Billion To Ramp Up New Drug Innovation

SHANGHAI - China will invest RMB 6.6 billion ($960 million) to launch a massive new drug development and manufacturing program from 2008 to 2010. Roughly 3,290 projects focused on preclinical studies and identifying new candidates are awaiting approval to initiate in 2009

China’s Half Trillion Dollar Economic Stimulus Plan To Boost Healthcare Sector

BEIJING - China's new plan to inject RMB 4 trillion into the economy to stimulate growth and counter the effects of the global financial crisis will boost the overall health care sector and propel medical system reforms, according to analysts

China’s Health System Reforms Set To Spark Hospital Construction Boom And Boost Medical Device Makers

[Editor's note: This is part two in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes and access to medicines. Part one appeared in PharmAsia News on Oct. 30, 2008.]





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts